303 related articles for article (PubMed ID: 27021607)
21. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC
Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
Zhang H; Chen J; Zhang Y; Zhao N; Xu D
Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.
Urowitz MB; Ohsfeldt RL; Wielage RC; Dever JJ; Zakerifar M; Asukai Y; Ramachandran S; Joshi AV
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33051264
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
[TBL] [Abstract][Full Text] [Related]
27. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
28. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Lupus; 2016 Jun; 25(7):699-709. PubMed ID: 26936891
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
[TBL] [Abstract][Full Text] [Related]
30. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R;
Lupus; 2013 Feb; 22(2):144-54. PubMed ID: 23213069
[TBL] [Abstract][Full Text] [Related]
31. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
32. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
Lokhandwala T; Yue B; Coutinho AD; Bell CF
Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
[TBL] [Abstract][Full Text] [Related]
33. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
[TBL] [Abstract][Full Text] [Related]
35. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
[TBL] [Abstract][Full Text] [Related]
36. Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials.
Xie W; Huang H; Zhan S; Zhang Z
Lupus Sci Med; 2021 Oct; 8(1):. PubMed ID: 34697129
[TBL] [Abstract][Full Text] [Related]
37. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.
Dimelow R; Ji B; Struemper H
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):622-633. PubMed ID: 33245847
[TBL] [Abstract][Full Text] [Related]
39. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
40. Update on belimumab for the management of systemic lupus erythematosus.
Lutalo PM; D'Cruz DP
Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
